Cannabis reform is usually described as a movement across a legal boundary.
A court recognises a right. A government removes criminal penalties. Medical use becomes lawful. Adults may cultivate a limited number of plants. A regulated market opens.
These changes can protect people from arrest, prosecution, loss of employment, family disruption, and imprisonment. Conduct once treated as inherently illegitimate now enters the law as something governments are prepared to permit.
Once a government accepts some lawful conduct involving cannabis, it must decide who may participate, where cannabis may come from, which products are allowed, how much a person may possess, and which penalties remain outside authorised channels.
Across multiple jurisdictions, governments have recognised limited rights while leaving essential access routes blocked. They have added conditions, retained sanctions around the permitted boundary, and admitted licensed operators through routes most ordinary people can’t use.
The legal language changes before the institutions built under prohibition surrender control over access, supply, product form, and participation.
The previous issue asked which forms of cannabis survive as evidence moves through policy, regulation, and market design. This issue follows the same institutional process into another question:
Which people, purposes, and forms of participation survive recognition?
Rights without routes
A legal right can only be exercised through its established channel. A person may be allowed to possess cannabis and still have no lawful way to obtain it. Private cultivation may be protected while access to seed or plant material remains unresolved. Medical use may be recognised while consultations or approved products remain scarce or unaffordable.
South Africa provides a clear example. The Constitutional Court’s 2018 Prince judgment protected adult use, possession, and cultivation in private through a narrow exception to existing criminal offences.
Josh Swart’s July 2026 position paper for Stellenbosch University’s Criminal Law Colloquium describes this as privacy-based decriminalisation. The judgment created no general adult-use market or lawful supply system.
The Cannabis for Private Purposes Act was signed in 2024 and has not yet commenced. Section 8 requires the President to bring it into operation by proclamation. The immediate legal position remains governed by Prince, read alongside the Drugs and Drug Trafficking Act and Medicines Act. Draft regulations published in February 2026 proposed numerical limits for possession and cultivation without a clear public explanation of how those figures were calculated.
Privacy also constrains the legal or social frameworks adults can establish around sanctioned behaviour. Prince protects a personal sphere centred on private possession, use, and cultivation. In The Haze Club, the court refused to treat a closed membership model as part of that protected sphere.
Collective cultivation, storage, and allocation move toward the dealing offences that remained in place.
Private cannabis clubs emerged because many adults can’t grow at home. Some use closed membership, inventory records, product testing, and tax compliance. These controls can make a club more accountable, yet the law provides no recognised category for collective cultivation or member-based distribution.
South Africa recognised private adult conduct without creating the legal structure needed to organise access to it.
People with suitable space, time, knowledge, and viable plant material can exercise the recognised freedom more easily. People in crowded housing, restricted rentals, or homes where cultivation is impractical face a substantially more restrictive route. While the right exists for everyone on paper, its real-world value depends on resources distributed unequally across the population.
The licence changes the status of the person
Licensing can establish traceability, inspection, and accountability. It also changes the legal status of the person carrying out the conduct. Cultivation becomes authorised production. Possession becomes inventory. Supply becomes a regulated commercial service.
Canada demonstrates the contradiction in a mature legal market. Adults may possess limited amounts, cultivate up to four plants per household where provincial rules allow it, and share limited quantities with other adults. Selling without authorisation remains illegal, and unauthorised production or distribution can still result in imprisonment.
Licensed companies and their employees may cultivate, process, possess, and distribute cannabis at a commercial scale. Canada’s Cannabis Act expressly allows licence holders, employees, and contractors to perform activities that would otherwise fall within prohibited categories when they act within the licence.
Large-scale production creates responsibilities that don’t arise in the same form for a household cultivator or a person supplying a known adult. Yet lawful participation depends heavily on premises, capital, security systems, professional advice, testing arrangements, and the ability to survive regulatory delay. Formal compliance is favoured over practical experience and community relationships.
Authority to supply is granted only to those who can afford the route.
Conditions become the access system
Post-recognition control is increasingly exercised through conditional frameworks. Possession is lawful below a threshold. Cultivation depends on location. Medical access requires professional approval.
Supply passes through approved producers, products, laboratories, and distribution channels.
Germany’s 2024 Cannabis Act permits adults to possess limited quantities, cultivate up to three plants for personal use, and obtain cannabis through licensed non-profit cultivation associations. It created meaningful protection without a general commercial retail market. Lawful supply remains routed through home cultivation and tightly regulated associations.
Some conditions address identifiable risks, including contamination, youth access, and impaired driving. Others make conduct easier to monitor or reduce the number of people regulators must supervise.
Quantity limits decide when possession changes legal character. Product standards decide which forms remain available. Licensing costs decide who can participate.
Regulators choose the impact of each measure and decide who bears the burden.
Medical recognition and the limits of autonomy
Medical cannabis programmes have protected patients, enabled clinical support, and created lawful access to tested products. They also confine legitimacy to a recognised patient, a therapeutic purpose, and an approved professional route. Diagnosis and prescription act as the gatekeepers to approval.
Thailand shows how medical legitimacy can restrict broader access. Cannabis flower was removed from the narcotics list in 2022, producing widespread availability under an incomplete framework. In June 2025, the Ministry of Public Health reclassified flower as a controlled herb and required a prescription for lawful retail purchase. Licensed shops had to source from certified farms, report their sources, and limit sales to a prescribed 30-day quantity.
The government cited youth access, rapid retail expansion, and use outside medical purposes. Thailand’s policy remains politically contested, but the mechanism is clear: practical adult access was restricted by restoring medical certification as the only permissible route to lawful purchase.
South Africa’s Section 21 system makes the access problem even more visible. A treating practitioner may apply to SAHPRA for a named patient to use a specified unregistered cannabis medicine. Approval attaches to that product and its authorised supply chain. Patients cannot substitute locally available flower, even where it has been cultivated, tested, or supplied responsibly.
Approved access has often depended on imported products, while South African cultivators export cannabis for regulated medicinal markets. The patient’s need is recognised only when it passes through an approved product and supply route. Locally available cannabis remains outside that pathway.
Clinical systems assess symptoms, contraindications, dosage, and treatment response. Adult autonomy covers decisions that don’t require any clinical justification. People consume alcohol, follow demanding diets, undertake risky recreation, and make intimate personal choices without first proving a therapeutic need.
Governments and regulators continue to favour medical classification because a prescriber can approve, document, and withdraw access. Standard adult access limits institutional capacity to exert ex-ante control over the decision-making process.
Sanctions move to the boundary
Recognition seldom removes punitive authority entirely. Possession remains lawful until a quantity threshold is crossed. Cultivation is protected until the plant count, location, or purpose changes. Sharing may be allowed while sale remains criminal. Medical use may be lawful through a prescription and punishable outside it.
South African cannabis clubs sit directly on this boundary. Prince did not protect buying, selling, or collective supply, and Parliament’s enacted framework creates no club category. It defines consideration to include compensation, a gift, a reward, a favour, or a benefit. Dealing includes providing or receiving cannabis for consideration and conduct that facilitates a sale.
Membership fees, cultivation contributions, administration charges, and storage fees may expose an entire club arrangement to a dealing offence carrying a maximum sentence of ten years once the Act commences. A court may view payment, cultivation, allocation, and collection as one supply transaction. Private use receives recognition. The organised route that makes access possible remains exposed to severe criminal sanctions.
Reduced penalties can still involve confiscation, police contact, court appearances, employment consequences, or a criminal record. Residual enforcement falls most heavily on those with the fewest routes into the authorised system. Private property keeps cultivation out of view. Disposable income secures licensed products. Medical access provides documentation. People without those advantages remain visible to police and more dependent on informal supply.
Governments are licensing conduct to capital while continuing to punish people for performing materially and morally similar conduct outside the licensed system.
Harm becomes administrative leverage
Cannabis can cause harm, yet the risk varies with age, health, potency, frequency, route of administration, and individual vulnerability. Evidence of harm begins a policy process in which institutions decide who the evidence applies to, how strong the causal claim is, and whether the proposed response is proportionate.
Findings about heavy adolescent use can support age restrictions and targeted prevention. The same evidence can be extended into limits on adult product choice. Concerns about high-potency products may support differentiated controls and can also be used to treat flower, adult use, and decentralised supply as one category of threat.
The 2026 DEA rescheduling hearing provided a current example. Opposition testimony ranged across youth exposure, psychosis, impaired driving, workplace testing, illicit cultivation, and failures in state-regulated markets. While these concerns warrant scrutiny, their inclusion expanded a narrow, technical scheduling decision into a sweeping assessment of nearly all harms associated with cannabis and its reform. The inherited Schedule I position remained the baseline, while the case for change had to address risks that Schedule III would neither legalise nor remove from federal control.
Cannabis clubs illustrate the proportionality problem. Risks involving minors, contamination, diversion, and misleading sale can be regulated directly. A closed membership model that records inventory, tests products, and limits access to adults presents a different risk from conventional trafficking.
Subjecting both to identical criminal provisions forces the justice system to absorb functions better suited for a regulatory framework.
The regulation of vehicles, alcohol, and firearms demonstrates that the potential for serious harm does not inherently justify prohibition. Governments manage vehicles through driver eligibility, testing, road rules, insurance, and sanctions for dangerous conduct. Alcohol remains available under age limits, sales licensing, taxation, and penalties linked to harmful behaviour. Jurisdictions that permit civilian firearms use screening, licensing, recordkeeping, storage rules, and criminal sanctions for misuse.
All these systems begin with managed adult access. Governments process conduct involving cannabis through institutions inherited from prohibition. Controlled-drug systems were built around prior authorisation, and police, health departments, medicines regulators, and courts still use categories formed when almost all unauthorised conduct involving cannabis was presumed unlawful.
International law reinforces that baseline. The 1961 Single Convention limits controlled substances to medical and scientific purposes. Cannabis and cannabis resin were removed from Schedule IV in 2020 after their medical value was recognised, but remain in Schedule I. The International Narcotics Control Board continues to regard state-authorised non-medical markets as inconsistent with the treaty framework.
While treaties may bind signatories, they still leave governments choices around possession, proportionality, and alternatives to punishment. Institutional pressure still favours medical and scientific access because those routes fit the inherited system. For lawmakers, the political cost of a post-reform crisis is much higher than the ongoing toll of prohibition and arrest.
Institutions process harms associated with cannabis use through a prohibitionist architecture. They process harms involving alcohol, firearms, and vehicles through systems designed for managed adult access. Distinct legal baselines dictate entirely different policy trajectories.
Technical concerns become policy choices
Regulating cannabis products and cultivation presents several practical problems. The product’s strength and composition change from batch to batch, and cultivation can leave behind harmful pesticides or contamination. Smoking also poses risks to lung health, though some product forms make accurate dosing much easier.
Governments can respond through testing, contaminant limits, warnings, age restrictions, and information about dose and onset. Flower makes the policy choice visible. It’s biologically variable and can be smoked, but can also be tested, labelled, vaporised, and supplied under standards designed for its form. Germany already permits medicinal flower under prescription and pharmaceutical controls.
Regulators decide whether variability calls for batch testing or removal from the lawful category. They decide whether combustion risk calls for public-smoking restrictions or denial of access to the plant material. Ordinary consumer regulations don’t usually prescribe how many bottles of beer, wine, spirits, or cartons of cigarettes an adult may keep at home. Cannabis quantity ceilings need a justification tied to diversion or supply rather than a general claim of public-health risk.
Flower can be cultivated at a small scale and used with limited processing. Standardised extracts, metered devices, and pharmaceutical formulations require specialised equipment and capital. Rules that favour highly processed forms direct lawful participation toward those institutions capable of manufacturing them.
Procedure restricts recognition
Legislation establishes a framework. Regulations and administrative practice then determine how it operates through licences, prescribing rules, testing thresholds, police interpretation, and court decisions.
South Africa’s movement from Prince to an uncommenced Act and draft regulations shows how a privacy principle becomes a detailed system of quantities and offences without producing a lawful category for collective adult access. Malta established non-profit cannabis associations, Germany introduced cultivation associations, and Uruguay permits registered clubs. Each retains sanctions for diversion and unlicensed supply while separating regulated collective access from trafficking.
Germany also shows how access can contract through procedure. Its 2024 reforms removed medicinal cannabis from the narcotics framework and expanded access. Rising imports and concern about online prescribing led the federal government to propose face-to-face consultations and an end to mail-order medicinal flower in 2025. At a Bundestag health committee hearing in January 2026, some participants supported stronger controls while others warned of disproportionate effects on patients.
Higher imports don’t establish that every additional prescription lacked medical legitimacy. Online prescribing can enable weak assessment and can also help patients who live far from specialist clinicians or have limited mobility. Targeted prescribing standards and follow-up requirements would place the burden closer to the identified problem than a broad restriction.
Well-resourced institutions enter these processes with lawyers, technical specialists, data, and staff who can sustain long engagements. Patients, small cultivators, informal suppliers, and established cannabis communities often rely on practical knowledge that must be translated into legal or clinical language before institutions accept it. A formally open process can still distribute influence unevenly.
The DEA hearing held in July 2026 showed how that imbalance can shape the record itself. Seven outside participants opposing broader rescheduling were admitted to present evidence, while independent reform organisations were excluded from appearing as designated parties and cross-examining witnesses. Opponents received repeated opportunities to challenge the government’s case.
The harms created by continued Schedule I control, including criminal exposure and restricted access, received little representation. The resulting record gave extensive space to reasons for caution while giving limited attention to the costs of preserving the existing classification.
Restrictive policies gain political strength when presented as public safety measures. Governments promise to protect children, prevent diversion, and strengthen medical oversight. The scope of the response determines whether it stays connected to the conduct that created the risk.
Permission becomes the operating model
Recognition is operationalized through clear legal allowances: limited adult possession, patient access to approved products, commercial cultivation by licensed firms, and personal cultivation for individuals with adequate private space.
The exclusions determine the reach of those permissions. A person without private space can’t use the cultivation route. Someone without medical approval can’t use the clinical route. A small supplier can’t use the commercial route. A community cultivator without capital can’t cross the licensing threshold.
Rights recession can occur without formal repeal. Governments restrict routes, add conditions, exclude product forms, and raise the cost of lawful participation. Licensed capital then follows the lawful route, meeting the demand created by recognition while ordinary people remain prohibited from supplying one another.
No coordinated master plan is required. Decisions about security, testing, premises, distribution, and medical oversight accumulate across the system and favour actors capable of sustaining formal compliance.
The state has accepted that the conduct can be legitimate. It now decides whose conduct receives permission.
#
